Liposomal Bupivacaine is Not Associated with a Higher Rate of Surgical Site Infections

Send us Fan MailEver wondered if advanced pain relief for pets could compromise their recovery from surgery? That's the burning question we tackle with Drs. Camille Andrews and Rachel Williams as they unpack the results of their study on liposomal bupivacaine, or Nocita, in dogs and cats undergoing gastrointestinal surgery. Camille and Rachel discuss how Nocita measures up to the veterinary community's expectations, squashing fears of increased surgical site infections or the emergence of antibiotic-resistant superbugs. We get the inside scoop on the motivations behind this research, from Nocita's 72-hour pain relief window to addressing off-label usage concerns to considering the financial aspect for pet owners. You won't want to miss this important episode!JAVMA article: https://doi.org/10.2460/javma.23.08.0463INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ®  OR AJVR ® ?JAVMA ® : https://avma.org/JAVMAAuthorsAJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® :Facebook: Journal of the American Veterinary Medical Association - JAVMA | FacebookInstagram: JAVMA (@avma_javma) • Instagram photos and videosTwitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | FacebookInstagram: AJVR (@ajvroa) • Instagram photos and videosTwitter: AJVR (@AJVROA) / TwitterJAVMA ®  and AJVR ®  LinkedIn: https://linkedin.com/company/avma-journals